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Abstract
Premenstrual syndrome is a common chronic disorder in most women of reproductive age. The main symptoms are depression, anxiety, tension, 
feeling out of control, and mastalgia. In premenstrual syndrome, the effects of aromatic edible Elsholtzia splendens and  Cirsium japonicum were
investigated for over 3 months in 30 women participants in their twenties. In the Elsholtzia splendens capsule treated group, scores of depression
and anxiety were significantly lower than those in the Cirsium japonicum capsule treated group. Moreover, instability of the premenstrual assessment
form was significantly decreased in the Elsholtzia splendens capsule treated group. Our results suggest that Elsholtzia splendens could be an effective 
plant material in relieving symptoms of premenstrual syndrome.
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Introduction5)
Premenstrual syndrome (PMS) is a common chronic disorder 
that can affect women's interpersonal relationships, social 
behavior, work absenteeism, and work productivity [1]. Most 
women in the reproductive age have one or more emotional or 
physical symptoms in the premenstrual phase of the menstrual 
cycle. The symptoms are often mild, but 5-8% has severe 
symptoms that are associated with substantial distress and 
functional impairment. Mood and behavioral symptoms, including 
irritability, tension, depressed mood, tearfulness, and mood 
swings are the most distressing, but somatic complaints such as 
breast tenderness and bloating can also be problematic [2-4]. In 
medical reports, clinically significant premenstrual symptoms 
were named premenstrual syndrome (PMS) or premenstrual 
tension (PMT). The World Health Organization's International 
Classification of Disease (ICD) includes “Premenstrual Tension 
Syndrome” under the heading of “disease of the genitourinary 
tract”. 
For managing premenstrual syndrome, various treatments were 
suggested: cognitive behavioral therapy, lifestyle change, dietary 
supplement (Vitamin B6, calcium), herbal/complementary therapies, 
estradiol patches, and oral progestogens therapy [5-10]. Patients 
who seek medical help for PMS symptoms have usually 
implemented lifestyle changes and tried most over-the-counter 
remedies. However, before any medical treatments are commenced, 
it is still important to confirm that all appropriate lifestyle 
changes have been made. Recently, traditional herbal medicine 
was evaluated for relieving premenstrual syndrome [10].
Elsholtzia splendens is a Korean perennial, aromatic, and 
medicinal plant which belongs to the Labiatae family. Because 
Elsholtzia splendens contains volatile oil and flavonoids, the 
edible flower and leaves of this plant are primarily used for 
perfume and medicinal purposes [11]. Previous studies reported 
that Elsholtzia splendens had effects on reducing inflammation 
and fever [12]. 
Cirsium japonicum, a plant grown world-widely, is a perennial 
and medicinal plant which belongs to the Compositae family. 
The compounds most often reported for Cirsium japonicum are 
apigenin, cirsimaritin, kaempferol, linarin, luteolin, pectolinarin, 
and quercetin. Among them, linarin and pectolinarin are known 
to have anti-inflammatory properties [13]. Recently, the antidepre-
ssant effect of Cirsium japonicum was reported using an open 
field test and a forced swimming test [14]. Among the different 
plant parts of Cirsium japonicum, the leaves had the highest level 
of total flavonoids and apigenin content followed by the flowers 
and stems [15]. 
Considering the aforementioned effects (reducing pain and 
antidepressants effects) of Cirsium japonicum and Elsholtzia 
splendens, it seemed appropriate to evaluate their effects on 
relieving premenstrual syndrome. Hence, the objective of 
this study was to evaluate the effects of aromatic edible 
Elsholtzia splendens and Cirsium japonicum on premenstrual 
syndrome. 
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Table 1. Formula for capsules of Cirsium japonicum and Elsholtzia splendens
Material Contents (mg) 
/Capsule Percentage (%)
Freeze-dried powder of Cirsium japonicum
or  Elsholtzia splendens 120.00 60.00
Lactose 73.60 36.50
Gelatin 3.52 1.76
Carboxymethyl cellulose-Na 0.88 0.44
Magnesium stearate  2.00 1.00
Total 200.00 100.00
Table 2. Demographics characteristics 
Variables
Elsholtzia 
splendens 
group
Cirsium 
japonicum 
group
Placebo 
group Total
Sex (female)  10 10 10 30
Age (yr) 23.00 ± 0.94 23.10 ± 1.79 22.60 ± 1.65 22.90 ± 1.47
Menarchial age  13.70 ± 1.83 13.10 ± 1.66 13.40 ± 0.70 13.40 ± 1.45
Menstrual cycle 29.90 ± 2.23 30.50 ± 2.88 32.20 ± 4.21 30.87 ± 3.26
Menstrual duration 5.80 ± 1.03 6.00 ± 1.05 6.90 ± 1.37 6.23 ± 1.22
Values  are  the  mean ± SD. 
Table 3. The subordinate symptoms of the premenstrual assessment form 
(PAF) 
The subordinate factors of PAF
1. Low mood / Loss of pleasures 10. Impulsiveness
2. Endogenous depressive features 11. Organic mental discomfort
3. Instability 12. General physical discomfort 
4. Atypical depressive features 13. Sign of water retention
5. Hysteroid features 14. Autonomic physical changes
6. Hostility / anger 15. Fatigue
7. Social withdrawal 16. Impaired social functioning
8. Anxiety 17. Miscellaneous mood / behavior
9. Increased well-being 18. Miscellaneous physical changes
Subjects and Methods
Formula for capsules of Elsholtzia splendens and Cirsium 
japonicum 
Samples of the aerial parts of Elsholtzia splendens and 
Cirsium japonicum were collected from Gyeonggi-do in the 
Republic of Korea. The plants were identified and authenticated 
by a botanist at the Korea National Arboretum. Samples were 
freeze-dried (FD5505, IlShin LabTech, Seoul, Korea) and the 
leafless woody stalks were discarded. The dried samples were 
subsequently crushed for 10 sec using a blender (HMC-400T; 
Hanil Electronics, Seoul, Korea), and then capsules were made 
as shown in Table 1. According to our previous experiment of 
total flavonoids and apigenin, the acceptable daily intake of both 
samples was 120 mg.
Subjects
To recruit female participants for this study, in November 2006 
we advertised to students at Duksung Women's University in 
Seoul, Korea, entitling the study, “PMS Management Program”. 
All applicants were obliged to participate in an interview with 
this being the psychological assessment tool for screening. 
Thereafter, a total of 30 participants with PMS were selected 
from the interview and screening tests with the exception of those 
who 1) had missed menstruation cycles for more than 3 terms 
2) had taken the contraceptive pill, or 3) were evaluated as 
unsuitable participants for this program because of serious mental 
illness as per SCL-90-R (Symptom Checklist-90-Revision). 
Thirty participants were assigned to 3 groups, Elsholtzia 
splendens group (n = 10), Cirsium japonicum group (n = 10), and 
placebo group (n = 10) according to 1) age 2) Premenstrual 
Assessment Form (PAF) score 3) Beck Depression Inventory 
(BDI) score and 4) State-Trait Anxiety Inventory (STAI) score. 
In addition, participants were asked to quit taking anesthetic 
alleviative or contraceptive pills during this program, and to 
record their daily PMS symptoms in a diary for monitoring and 
assessment purposes. The capsules for two weeks were put in 
a sanitary bag and provided to the participants. The participants 
had to present once every two weeks with their PMS ‘Symptoms 
Diary’ and discuss any changes in symptoms. In total, the 
participants were to take 1 capsule per day, every morning 30 
minutes after waking up for 3 months. After an experimental 
period of 3 months, they were asked to submit their PMS ‘Symptoms 
Diary’ and to be re-tested using the same methodology conducted 
previously. The participants’ mean age was 22.9 and the mean 
of the PAF score was 257.57 as shown in Table 2.
Beck Depression Inventory (BDI) 
The BDI was utilized to assess depressive symptoms of the 
participants [16]. The BDI has 21 questions that measure the 
types and the severity of depression. The questions include 
emotional, cognitive, and motivational changes related to 
depression experienced in daily life. The higher score means the 
more serious depression. The Cronbach's α  (reinstability 
coefficient) of the BDI in our study was 0.70. 
State-Trait Anxiety Inventory (STAI) 
To assess state anxiety, the STAI was assessed [4,17,18]. This 
inventory is useful for measuring state of anxiety of normal adults 
and distinguishing between clinically anxious people and the 
anxiety of psychiatric patients as well. Score ranges from 20 to 
80, with the higher score indicating more serious anxiety. The 
Cronbach's  α of the STAI in this study was 0.61. 
Premenstrual Assessment Form (PAF) and Premenstrual 
Assessment Form-Past Cycle Version (PAF-PCV) 
In this study, the PAF and Unipolar Summary Scales of the 
PAF-PCV were utilized to assess changes of emotional, 
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Table 4. The comparison of depression and anxiety scores among groups
Variables Treatment Elsholtzia splendens group (n = 10) Cirsium japonicum group (n = 10) Placebo group (n = 10) P
Depression (BDI)
1) pre 33.50 ± 5.82 33.60 ± 8.8 33.70 ± 6.11 0.001**
post 23.60 ± 4.79 30.40 ± 5.40 33.00 ± 5.33
Anxiety (STAI)
2) pre 59.40 ± 7.30 50.90 ± 9.50 55.60 ± 9.85 0.027*
post 48.10 ± 5.20 52.00 ± 6.18 57.10 ± 9.10
V a l u e s  a r e  t h e  m e a n±S D .  *P < 0.05,  ** P < 0.01 
1) Beck  Depression  Inventory  (BDI) 
2) State-Trait  Anxiety  Inventory  (STAI) 
[6,19]. The PAF is a measure for retrospectively evaluating the 
PMS symptoms of menstrual duration during the previous 3 
cycles and the PAF-PCV is a retrospective measure for evaluating 
PMS symptoms of menstrual duration in the past 1 cycle after 
the treatment. This scale is a 95-item self-report measure and 
the total score ranges from 95 to 570 with the highest score 
indicating more serious symptoms. The PAF emphasized the 
variations of symptoms from 14~17 days before menstruation 
to the next period of menstruation. This scale in our study 
consisted of 18 subordinate symptoms (Table 3). The Cronbach's 
α was 0.94. 
Statistical analysis 
All data are expressed as mean ± standard deviation values. 
Statistical significance was evaluated by ANOVA and the Scheffe 
test (SPSS 14.0 version). Differences between and among means 
were considered significant when the P value was 0.05 or 0.01. 
Results
The comparison of pre-post scores on depression and anxiety 
among groups 
Effect of Elsholtzia splendens and Cirsium japonicum on 
premenstrual syndrome was studied via three experimental 
groups of thirty women with an average age of 22.9 years: 1) 
the Elsholtzia splendens group 2) the Cirsium japonicum group 
and 3) the placebo group. Participants of the experiment were, 
in mean menarchial age, 13.40 ± 1.45 years old. In addition, their 
menstrual cycle was 30.87 ± 3.26 days and the menstrual duration 
was 6.23 ± 1.22 days (Table 2). According to our previous 
experiment of total flavonoids and apigenin, the acceptable daily 
intake of Elsholtzia splendens and Cirsium japonicum sample 
was 120 mg. The Elsholtzia splendens group and the Cirsium 
japonicum group were instructed to take 1 capsule per day (which 
contained 120 mg of Elsholtzia splendens or Cirsium japonicum 
respectively), every morning 30 minutes after waking up. As for 
the placebo group, participants took capsules which were exactly 
the same, except for the absence of the plant material. This 
experiment was conducted for 3 consecutive months. Before a 
statistical demonstration, this study conducted the test about the 
equality of variances. As a result, the dispersion of the 3 groups 
was equal. In addition, ANOVA was analyzed to examine if there 
were significant differences of the pre-post scores on depression 
and anxiety among the 3 groups. The results showed that three 
groups significantly differed from the pre-post score of 
depression and anxiety. The pre-post scores of depression (BDI) 
were decreased from 33.50 to 23.60 in the Elsholtzia splendens 
group, from 33.60 to 30.40 in the Cirsium japonicum group, and 
from 33.70 to 33.00 in the placebo group. Finally, we discovered 
a greater decrease in the pre-post scores in the Elsholtzia 
splendens group than in other groups (P < 0.01). The pre-post 
scores of anxiety were decreased from 59.40 to 48.10 in the 
Elsholtzia splendens group, but there were increases from 50.90 
to 52.00 in the Cirsium japonicum group and from 55.60 to 57.10 
in the placebo group. Finally, there were greater decreases of 
anxiety scores in the Elsholtzia splendens group than in other 
two groups (P < 0.05). Moreover, the result of the Scheffe test 
showed that the post scores of depression and anxiety in the 
Elsholtzia splendens group were decreased more than in other 
groups (Table 4). 
The comparison of pre-post scores on total and subordinate 
symptoms of the Premenstrual Assessment Form (PAF) 
The significant differences between the three groups on the 
pre-post scores of the PAF were presented in Table 5. Although 
statistically significant differences of the total PAF scores were 
not found, the total scores of the PAF were decreased from 
270.20 to 176.70 in the Elsholtzia splendens group, from 257.30 
to 185.60 in the Cirsium japonicum group, and from 245.20 to 
207.00 in the placebo group. As a result, the total scores of the 
PAF in the Elsholtzia splendens group were not statistically 
significant, but presented greater decreases compare to other 
groups. However, the instability in subordinate factors showed 
a significant difference (P < 0.05). The pre-post scores of the 
instability were decreased from 11.50 to 6.40 in the Elsholtzia 
splendens group and from 11.80 to 8.30 in the Cirsium japonicum 
group, but there was an increase from 10.20 to 10.80 in the 
placebo group. Last but not least, the instability scores in the 
subordinate scales of the PAF in the Elsholtzia splendens group 
showed statistically more significant differences than other 
groups. In addition, although significant differences were not 
shown statistically in all scales (except for the instability), it was 
found out that there were changes of the mean score between 
the pre-post in all scales. In particular, the Elsholtzia splendens Mi-Sook Chung
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Table 5. The comparisons of the total scores and subordinate scales of the premenstrual assessment form (PAF)
Variables Treatment Elsholtzia splendens group (n = 10) Cirsium japonicum group (n = 10) Placebo group (n = 10) P
Total PAF scores pre 270.20 ± 82.61 257.30 ± 74.81 245.20 ± 73.48 0.530
post 176.70 ± 61.33 185.60 ± 53.65 207.00 ± 67.47
Low mood / 
Loss of pleasures
pre 29.60 ± 12.09 28.30 ± 9.32 29.00 ± 12.61 0.319
post 20.20 ± 10.34 18.50 ± 6.02 24.40 ± 9.44
Endogenous 
depressive features
pre 15.60 ± 4.17 13.70 ± 5.01 14.30 ± 4.81 0.643
post 8.90 ± 4.12 9.90 ± 3.35 10.50 ± 3.92
Instability pre 11.50 ± 3.81 11.80 ± 2.82 10.20 ± 4.02 0.022*
post 6.40 ± 1.65 8.30 ± 3.06 10.80 ± 4.57
Atypical depressive 
features
pre 21.30 ± 6.75 21.70 ± 6.65 20.40 ± 5.84 0.623
post 14.50 ± 6.01 15.60 ± 6.00 17.20 ± 6.55
Hysteroid features pre 16.00 ± 6.06 15.90 ± 4.63 14.20 ± 6.46 0.101
post 10.30 ± 3.20 10.10 ± 4.18 13.80 ± 4.94
Hostility / Anger pre 19.00 ± 8.03 15.70 ± 5.40 14.80 ± 6.30 0.118
post 9.40 ± 3.03 9.90 ± 3.64 13.80 ± 7.27
Social Withdrawal pre 14.90 ± 4.73 14.10 ± 4.63 12.40 ± 5.95 0.446
post 7.50 ± 3.69 8.20 ± 3.91 9.90 ± 5.11
Anxiety pre 14.00 ± 5.62 12.10 ± 3.84 12.40 ± 4.03 0.824
post 8.70 ± 4.00 9.00 ± 2.87 9.70 ± 4.03
Increased well-being pre 5.40 ± 2.80 5.80 ± 2.00 5.60 ± 2.12 0.527
post 5.50 ± 1.84 5.90 ± 2.13 4.90 ± 1.91
Impulsiveness pre 11.60 ± 5.80 9.50 ± 3.90 9.70 ± 3.95 0.199
post 6.30 ± 2.41 7.80 ± 3.12 9.20 ± 4.61
Organic mental 
discomfort
pre 17.30 ± 8.74 15.40 ± 4.58 16.30 ± 6.77 0.962
post 12.70 ± 7.33 12.50 ± 3.57 13.20 ± 5.73
General physical 
discomfort 
pre 17.00 ± 5.01 17.50 ± 5.68 16.30 ± 6.00 0.208
post 11.50 ± 3.06 13.10 ± 5.55 15.70 ± 6.38
Sign of water retention pre 9.20 ± 3.12 9.00 ± 4.14 10.40 ± 4.65 0.323
post 6.30 ± 3.20 6.40 ± 2.55 8.20 ± 3.52
Autonomic physical 
changes
pre 17.30 ± 7.12 18.20 ± 7.69 17.10 ± 7.20 0.491
post 11.70 ± 4.17 15.10 ± 7.48 13.30 ± 6.77
Fatigue pre 14.30 ± 4.24 14.30 ± 3.90 14.70 ± 5.12 0.759
post 9.50 ± 4.04 9.30 ± 3.27 10.50 ± 4.20
Impaired social 
functioning
pre 31.40 ± 8.98 28.10 ± 8.41 28.80 ± 11.94 0.824
post 19.50 ± 7.43 21.40 ± 8.97 21.50 ± 7.72
Miscellaneous mood / 
Behavior
pre 30.40 ± 8.72 29.00 ± 8.74 27.60 ± 9.14 0.385
post 20.30 ± 6.09 19.50 ± 8.02 23.90 ± 8.08
Miscellaneous 
physical changes
pre 12.80 ± 4.32 16.40 ± 6.59 14.80 ± 5.96 0.302
post 9.30 ± 4.03 10.80 ± 3.62 10.90 ± 4.71
V a l u e s  a r e  t h e  m e a n±S D .  *P < 0.05,  ** P < 0.01
group revealed greater changes between the pre-post scores than 
other two groups. 
Discussion
Premenstrual syndrome is the consequence of fluctuations in 
the ovarian sex steroids leading to physical and behavioral 
symptoms. Many symptoms of premenstrual syndrome have been 
described: irritability, aggregation, depression, tension, anxiety, 
feeling out of control, bloatedness, and mastalgia are well-known 
symptoms [2-4,19]. In this study, depression and anxiety of the 
Elsholtzia splendens group were significantly decreased at the 
P < 0.01 and P< 0.05 respectively. As shown in Table 5, 
instability demonstrated significant decreases in the Elsholtzia 
splendens  group after the intake of the capsules (P <0 . 0 5 ) .  
Although there were no statistical significances, the total PAF 
scores indicated a decrease in the Elsholtzia splendens group after 
the intake. Our results revealed that Elsholtzia splendens is 
effective for decreasing depression, anxiety, and instability which 
are common symptoms of premenstrual syndrome. Therefore, 
Elsholtzia splendens is thought to be a useful plant material for 
relieving premenstrual syndrome. 
Recent investigation into the relief of premenstrual syndrome 
has employed hormone and antidepressant drugs, whereas 
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randomized placebo controlled study has shown that Agnus 
castus is an effective treatment for women with premenstrual 
syndrome. The effects were confirmed by the women's self- 
assessment and the investigator's evaluation [7]. The extensive 
treatment for St. John's wort as an antidepressant in women with 
severe premenstrual syndrome resulted in a significant relief of 
symptoms [7]. It was reported that evening primrose oil is of 
little value in treating premenstrual syndrome, except for the 
management of cyclical premenstrual mastalgia for which it is 
effective [2]. By utilizing Kampo which is Japan's traditional 
herbal medicine used to treat premenstrual syndrome, women 
who participated in the experiment reported improvements in 
their condition. In these studies, however, it was not revealed 
which compound of the herbal medicine was dedicated to the 
relief of premenstrual syndrome symptoms. As for the effect of 
carbohydrates on premenstrual syndrome symptoms, relatively, 
there are detailed explanations. In a study about whether mild 
to moderate premenstrual syndrome could be improved with a 
commercial, carbohydrate-rich beverage, the profile of mood 
states (tension & anxiety factors) showed a significant effect (P
< 0.05). The carbohydrate beverage probably acts by increasing 
the availability of tryptophan. This, in turn, may increase 
serotonin synthesis which reduces the mood and appetite 
disturbances accompanying PMS [6]. 
As mentioned above, our results strongly suggest that Elsholtzia 
splendens is effective for decreasing depression, anxiety, and 
instability which are common symptoms of premenstrual 
syndrome. According to our previous experiments, the amount 
of total flavonoid of flower and leaf of Elsholtzia splendens was 
2.52 mg/g and 1.99 mg/g, respectively. And the content of 
apigenin of flower and leaf was 18 ug/ml and 1.35 ug/ml, 
respectively [20]. In Cirsium japonicum, the amount of total 
flavonoid of flower and leaf was 1.54 mg/g and 2.58 mg/g, 
respectively. In addition, the content of apigenin of flower and 
leaf was 0.33 ug/ml and 2.73 ug/ml, respectively [15]. From the 
above data, the amount of total flavonoids for Elsholtzia 
splendens and Cirsium japonicum is similar, but the content of 
apigenin of Elsholtzia splendens is comparatively higher than 
those of Cirsium japonicum. We expect that, based on our 
previous research, biologically active compounds which had 
these effects are presumed to be flavonoid and apigenin from 
Elsholtzia splendens. Therefore, further study should clarify if 
flavonoid and apigenin extracted from Elsholtzia splendens 
decrease depression, anxiety, and instability. In addition, further 
experiments should be done to reveal its action mechanisms. 
In conclusion, effects of Elsholtzia splendens and Cirsium 
japonicum on premenstrual syndrome were studied through three 
experimental groups: 1) the Elsholtzia splendens group 2) the 
Cirsium japonicum group and 3) the placebo group. Elsholtzia 
splendens is significantly effective for decreasing depression, 
anxiety, and instability which are common symptoms of 
premenstrual syndrome. Therefore, Elsholtzia splendens may be 
a useful plant material for relieving premenstrual syndrome. 
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